Valbenazine was approved by the FDA for<unk>  in April 2017. Tetrabenazine, which is a dopamine depleting drug, is sometimes used to treat<unk>  and other movement disorders (e.g. Huntington's chorea). Deutetrabenazine, an isotopic isomer of tetrabenazine, was approved by the FDA for<unk>  in August 2017. Vitamin B6 has been reported to be an effective treatment for<unk>  in two randomised double-blind placebo-controlled trials, but the overall evidence for its effectiveness is considered "weak." Clonidine may also be useful in the treatment of<unk> , although dose-limiting hypotension and sedation may hinder its usage. Botox injections are used for minor focal dystonia, but not in more advanced<unk> . As of 2018 evidence is insufficient to support the use of benzodiazepines, baclofen, progabide, sodium valproate, gaboxadol, or calcium channel blockers (e.g. diltiazem).
Tardive dyskinesia
Akathisia
Focal dystonia
Torsion dystonia
Myoclonic dystonia
Paroxysmal dyskinesia
Pseudoathetosis
Dopamine-responsive dystonia